The abnormal expression of key molecules in the insulin signaling pathway, such as phosphatase and protein kinase, leads to hepatic IR, and these signal transduction changes in turn lead to the overexpression of key proteins in lipid metabolism, stimulating the liver to produce large amounts of VLDL-C, which subsequently triggers dyslipidemia [51]. The gene discussed is WEE1; the disease is metabolic syndrome.